Lucitanib for the Treatment of HR
Adult
Aged
Biomarkers, Tumor
/ genetics
Breast Neoplasms
/ drug therapy
Estrogen Receptor alpha
/ metabolism
Female
Gene Amplification
Humans
Middle Aged
Molecular Targeted Therapy
Naphthalenes
/ therapeutic use
Neoplasm Metastasis
Patient Safety
Protein Kinase Inhibitors
/ therapeutic use
Quinolines
/ therapeutic use
Receptor, ErbB-2
/ metabolism
Receptor, Fibroblast Growth Factor, Type 1
/ antagonists & inhibitors
Receptors, Progesterone
/ metabolism
Treatment Outcome
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 01 2020
15 01 2020
Historique:
received:
09
04
2019
revised:
04
07
2019
accepted:
09
10
2019
pubmed:
18
10
2019
medline:
2
10
2020
entrez:
18
10
2019
Statut:
ppublish
Résumé
The Patients with HR Seventy-six patients (32/18/26 in cohorts 1/2/3) from nine countries were enrolled. The prespecified primary endpoint was met in cohort 1 with ORR of 19% [95% confidence interval (CI), 9%-35%], but not in cohorts 2 and 3 with ORR of 0% (95% CI, 0%-18%) and 15% (95% CI, 6%-34%), respectively. Frequent adverse events included hypertension (87%), hypothyroidism (45%), nausea (33%), and proteinuria (32%). Exploratory biomarker analyses suggested higher ORR in patients with high Lucitanib had modest antitumor activity and significant hypertension-related toxicity in patients with HR
Identifiants
pubmed: 31619444
pii: 1078-0432.CCR-19-1164
doi: 10.1158/1078-0432.CCR-19-1164
doi:
Substances chimiques
Biomarkers, Tumor
0
E-3810
0
ESR1 protein, human
0
Estrogen Receptor alpha
0
Naphthalenes
0
Protein Kinase Inhibitors
0
Quinolines
0
Receptors, Progesterone
0
ERBB2 protein, human
EC 2.7.10.1
FGFR1 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Receptor, Fibroblast Growth Factor, Type 1
EC 2.7.10.1
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
354-363Informations de copyright
©2019 American Association for Cancer Research.